Phenazopyridine-Induced Methaemoglobinaemia - The Aftermath of Dysuria Treatment
  • Amina Hamza
    Department of Medicine, Allegheny Health Network, Pittsburgh, PA, USA
  • Adeel Nasrullah
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, PA, USA
  • Romil Singh
    Department of Medicine, Allegheny Health Network, Pittsburgh, PA, USA
  • Briana DiSilvio
    Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, PA, USA

Keywords

Methaemoglobinaemia, phenazopyridine, urinary tract infection, serotonin syndrome, arterial blood gas, methylene blue, case report

Abstract

Introduction: Phenazopyridine is an over-the-counter urinary analgesic commonly used to alleviate the burning and urgency associated with lower urinary tract infections. Methaemoglobinaemia is an uncommon adverse effect of phenazopyridine use. We report a case of methaemoglobinaemia in a patient prescribed daily phenazopyridine to treat urethral and bladder irritation caused by a chronic indwelling Foley catheter.

Case description: A 55-year-old female resident of a long-term acute care facility with a chronic Foley, tracheostomy and ventilator-dependent respiratory failure was observed to have generalized dusky skin and hypoxia. Pulse oximetry was reading in the high 80s despite administration of 100% FiO2. ABG revealed paO2 of 451, oxyhaemoglobin level 75% and methaemoglobin level 22%. Medication review indicated that the patient was prescribed phenazopyridine 400 mg TID for the previous 2 months. This medication was discontinued. Considering she was chronically taking mirtazapine, she can increase risk of serotonin syndrome should she be administered first-line treatment with methylene blue. Vitamin C was thus instead administered as a second-line agent. Serial ABGs showed a rapid decline in methaemoglobin levels and an increase in oxyhaemoglobin within 2 days.

Discussion: Acquired methaemoglobinaemia is a rare adverse effect of treatment with phenazopyridine. This risk increases when drug dosage and duration exceed manufacturer specifications. Treatment typically includes cessation of the offending drug and administration of methylene blue in severe cases. A thorough medication reconciliation should be performed prior to methylene blue initiation, as patients taking serotonergic medications (for example, MAOIs, SSRIs, SNRIs, TCAs) are at increased risk of serotonin toxicity with co-administration of methylene blue. In these instances, ascorbic acid/vitamin C can be chosen as an alternative treatment agent.

Conclusion: Work-up of refractory hypoxia should involve a thorough review of medications as even some over-the-counter drugs can cause the fatal side effect of methaemoglobinaemia. Treatment with vitamin C should be considered over methylene blue if serotonergic medications have been recently prescribed in order to avoid risk of serotonin syndrome.

VIEW THE ENTIRE ARTICLE

References

  • Medscape [Internet]. Phenazopyridine (Rx, OTC) [2019]. Available from: https://reference.medscape.com/drug/azo-standard-pyridium-phenazopyridine-343349.
  • Rehman HU. Methemoglobinemia. West J Med 2001;175(3):193–196.
  • Murphy T, Fernandez M. Acquired methemoglobinemia from phenazopyridine use. Int J Emerg Med 2018;11:45.
  • Shah PK, Kraft KH. Perioperative hypoxia secondary to phenazopyridine-induced methemoglobinemia in an adolescent patient without renal insufficiency or overdose: an unusual case. Urology 2019;130:142–143.
  • US Food and Drug Administration (FDA) [Internet]. FDA Drug Safety Communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications [2011]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-cns-reactions-possible-when-methylene-blue-given-patients.
  • Views: 1470
    HTML downloads: 114
    PDF downloads: 555


    Published: 2022-02-28
    Issue: 2022: Vol 9 No 2 (view)


    How to cite:
    1.
    Hamza A, Nasrullah A, Singh R, DiSilvio B. Phenazopyridine-Induced Methaemoglobinaemia - The Aftermath of Dysuria Treatment . EJCRIM 2022;9 doi:10.12890/2022_003191.